In this section
RICHMOND, Va.--(BUSINESS WIRE)--Jan. 24, 2002--Insmed Incorporated (Nasdaq:INSM) will announce financial results for its 2001 fiscal year and fiscal fourth quarter approximately 4:00 p.m. EST on Wednesday, January 30. The Company will host a conference call on Thursday, January 31, 2002, at 8:00 a.m. Eastern Time (7 a.m. Central Time). President, Chief Executive Officer and Chairman, Geoffrey Allan, Ph.D., will conduct the call that will give an overview of 2001 and provide an outlook for 2002. To participate in the conference call dial 877/709-5340, password: INSMED. A live audio feed of the webcast can be accessed through the Investor Relations link on the Company's website: www.insmed.com. A replay of the call will be available through the Investor Relations website beginning at 10:00 a.m.
About Insmed Incorporated
Insmed Incorporated is a biopharmaceutical company focused on the development of drug candidates for the treatment of type 2 diabetes and other metabolic and endocrine disorders associated with insulin resistance. The Company's lead product candidate, INS-1, is an orally active small molecule that restores insulin sensitivity to tissue. The Company is developing INS-1 for the treatment of type 2 diabetes and polycystic ovary syndrome, a significant women's health disorder. In conjunction to INS-1, the Company is developing SomatoKine®, a recombinant human protein that is targeted towards the management of both type 1 and type 2 diabetics who are less sensitive to insulin therapy. Further information is available at www.insmed.com.
CONTACT: Insmed Incorporated Baxter Phillips, III, 804/565-3041 firstname.lastname@example.org